Biotech IV Monitor

CRSP — CRISPR Therapeutics AG

$4.5B market cap · 5 upcoming readouts tracked

Clinical trial readout dates for CRISPR Therapeutics AG, compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is July 2028.

Next readoutJuly 2028in ~20 months
Upcoming readouts5none in Phase 3
Market cap$4.5B
Cash & investments$2.28B~20 quarters at last loss rate
Recent 8-K filings1latest 2026-11-02

Upcoming readouts

Phase 1/2 CTX340
Hypertension · NCT07758634
July 2028
Recruiting
Phase 1/2 CTX112
Progressive Multiple Sclerosis (PMS); Neuromyelitis Optica · NCT07804004
December 2029
Not Yet Recruiting
Phase 1/2 CTX112
B-cell Lymphoma; Non-Hodgkin Lymphoma · NCT05643742
January 2030
Recruiting
Phase 1/2 CTX460
Alpha-1 Antitrypsin Deficiency (AATD) · NCT07850076
June 2030
Recruiting
Phase 1/2 CTX112
Warm Autoimmune Hemolytic Anemia (WAIHA); ITP - Immune Thrombocytopenia · NCT07549698
December 2033
Recruiting

Cash position

CRISPR Therapeutics AG reported $2.28B in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-02). Its net loss for that quarter was $111M; at that rate the cash would last about 20 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.

Recent SEC filings

8-K Results of Operations — earnings, may carry pipeline updates2026-11-02

Companies working on similar indications

Discussion

No messages yet. If you follow CRSP, you can start the conversation.
Track CRSP in real time
See live implied volatility for CRSP and 106 other biotechs, and get alerted when a readout lands.
🔔 Alert me on CRSP
Contact — questions or corrections about CRSP: dukeupt@gmail.com